CasNo.1624262-20-9,C35H35ClNNaO3S Montelukast sodium 1624262-20-9,(1624262-20-9) Suppliers

1 Metric Ton	Negotiable

Min.Order :1 Metric Ton
Purity: 99.5%
Payment Terms : L/C,T/T,

Keywords

Montelukast sodium 1624262-20-9 C35H35ClNNaO3S

Quick Details

Appearance:Powder
Application:1624262-20-9
PackAge:Aluminium Foil Bag and Paper Drum
ProductionCapacity:100|Metric Ton|Day
Storage:1MT
Transportation:By Sea/Air/DHL

Superiority:

Our company was built in 2009 with an ISO certificate.In the past 5 years, we have grown up as a famous fine chemicals supplier in China and we had established stable business relationships with Samsung,LG,Merck,Thermo Fisher Scientific and so on.Our main business covers the fields below:

1.Noble Metal Catalysts (Pt.Pd...)

2.Organic Phosphine Ligands (Tert-butyl-phosphine.Cyclohexyl-phosphine...)

3.OLED intermediates (Fluorene,Carbazole,Boric acid...)

4.Customs Synthesis

Our advantage:

1. Higest quality and good package

2.Fast delivery

3.Better payment term

4.Fast response to customer within 6 hours

5.Good business credit in Europe ,US ,Japan ,Korea

Anyway ,if you need any chemicals from China ,Henan Tianfu can help you

Details:

Montelukast sodium Basic information

Pharmacological effect Uses

Product Name:	Montelukast sodium
Synonyms:	singulair;MONTELUKAST NA;MONTELUKAST SODIUM;mk-476;2-[1-[[1-[3-[2-[(7-chloro-2-quinolyl)]vinyl]phenyl]-3-[2-(1-hydroxy-1-methyl-ethyl)phenyl]-propyl]sulfanylmethyl]cyclopropyl]acetic acid sodium salt;1-[1-[[[(1R)-1-[3-[(1E)-2-(7-Chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropaneacetic;MK-476, Singulair;Montelukast, Sodium Salt
CAS:	151767-02-1
MF:	C35H35ClNNaO3S
MW:	608.17
EINECS:
Product Categories:	Active Pharmaceutical Ingredients;APIs;Chiral Reagents;Intermediates & Fine Chemicals;Pharmaceuticals;Sulfur & Selenium Compounds;Isotope Labeled Compounds;Pharmaceutical intermediates;DIOXYLINE;Other APIs;Inhibitors
Mol File:	151767-02-1.mol

Montelukast sodium Chemical Properties

storage temp.	-20°C Freezer, Under Inert Atmosphere
solubility	DMSO: ≥8mg/mL at 60°C
color	white to tan
Merck	14,6258

Safety Information

Hazard Codes	Xi
Risk Statements	63-41-62
Safety Statements	26
RTECS	GZ0698000

MSDS Information

Montelukast sodium Usage And Synthesis

Pharmacological effect	Cysteinyl leukotrienes (LTC4, LTD4, LTE4) is a eicosane-type substance released by various kinds of cells including mast cells and eosinophils with strong inflammatory effect. These important asthma pre-inflammatory mediators can bind to the Cysteinyl leukotriene receptors (CysLT) identified in the human airways, resulting in a variety of airway responses including bronchoconstriction, mucus secretion, increased vascular permeability, and eosinophil accumulation. Montelukast sodium is an orally active selective leukotriene receptor antagonist that can specifically inhibit the cysteinyl leukotriene receptor. It was successfully developed by the Merck Company (German) and had entered into market in Canada, Finland, and Mexican in 1997. It is suitable for the prevention and long-term treatment of adults and children asthma, including the prevention of daytime and nighttime asthma symptoms, the treatment of asthma patients who are aspirin-sensitive and prevention of exercise-induced bronchial contraction, it can also be used to relieve the seasonal allergic rhinitis symptoms of 15 year-old or over 15 year-old patients whose symptoms are invalid and intolerant to other treatment. Montelukast is a selective leukotriene receptor antagonist and has been approved for the oral administration treatment of asthma and allergic rhinitis. It is also a potent oral preparation that can significantly improve the inflammatory indicators. Biological determination of biochemistry and pharmacology has showed that montelukast sodium has a high affinity and selectivity to the CysLT1 receptors (compared with other kinds of pharmacologically important airway receptors such as prostanoid, cholinergic and β-adrenergic receptors). Montelukast can effectively suppress the physiological effects caused by the binding between LTC4, LTD4 and LTE4 receptor and CysLT1 receptor without any receptor agonistic activity. There is the secondary type of cysteinyl leukotriene receptor (CysLT2) presented in the lungs cysteinyl leukotriene receptor but may be limited to the blood vessels. So far, researchers haven’t cloned two receptors so the situation of CysLT receptor is illustrated through binding assay and pharmacological analysis. It has been now thought that montelukast does not antagonize CysLT2 receptors. The above information is edited by the chemicalbook of Dai Xiongfeng.
Uses	It can be applied to alleviate the symptoms caused by allergic rhinitis.
Uses	A selective leukotriene D4-receptor antagonist. Used as an antiasthmatic
Uses	antiinfective
Uses	A potent and highly selective CysLT1 receptor antagonist, without demonstrated CysLT2 activity